Citigroup’s Heart Test Laboratories HSCS Stock Holding History

Citigroup’s Portfolio HSCS Stock Details HSCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14	Closed	-$49	–	6222
2025 Q3	$49	Buy	+14	New	+$51	﹤0.01%	5855

Other funds holding HSCS

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

TFB Advisors Overland Park, Kansas $191M AUM 18.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ASW

Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's HSCS Position: Q4 2025 in Review

Citigroup sold out of Heart Test Laboratories (HSCS) in Q4 2025, closing a stake of 14 shares — an estimated $49 sold.

Citigroup first reported a position in HSCS in Q3 2025 and held it in 1 quarter. The position peaked at $49 in Q3 2025. 10 funds tracked by Wall St. Rank hold HSCS as of Q4 2025.

Citigroup reported no remaining Heart Test Laboratories position as of Q4 2025 after selling out during the quarter.
Citigroup sold 14 Heart Test Laboratories shares in Q4 2025, an estimated $49.
Citigroup first reported a position in Heart Test Laboratories in Q3 2025 and held it in 1 quarter.
Citigroup's Heart Test Laboratories position peaked at $49 in Q3 2025.
10 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.